Skip to main content
Equibles
RCUS logo

RCUS · Arcus Biosciences, Inc. · Earnings Call Transcripts & Audio

Track RCUS — free

Use RCUS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research RCUS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$25.83 +0.18 (+0.70%) At close · Sep 30
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$3.18B
Shares
127.33M
Volume · Sep 30 1.36M Avg daily vol (3M) 1.32M

Arcus Biosciences, Inc. Earnings Call Transcripts

Quarterly earnings calls for Arcus Biosciences, Inc. (RCUS), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲185.4% $27.00M −$67.00M '22 Q2 22-08-03 ▲248.8% $33.00M −$65.00M '22 Q3 22-11-02 ▼90.4% $34.00M −$67.00M '22 Q4 23-02-28 ▲38.9% $25.00M −$80.00M '23 Q1 23-05-09 ▲7.4% $29.00M −$75.00M '23 Q2 23-08-07 ▼3% $32.00M −$71.00M '23 Q3 23-11-07 ▼8.8% $31.00M −$81.00M '23 Q4 24-02-21 ▲480% $145.00M −$4.00M '24 Q1 24-05-08 ▲34.5% $39.00M −$93.00M '24 Q2 24-08-08 ▲50% $48.00M −$92.00M '24 Q3 24-11-06 ▼16.1% $26.00M −$94.00M '24 Q4 25-02-25 ▼80.7% $28.00M −$112.00M '25 Q1 25-05-06 ▲310.3% $160.00M $ '25 Q2 25-08-06 ▲26.9% $33.00M −$106.00M '25 Q4 26-02-25 ▼39.3% $17.00M −$128.00M '26 Q1 26-05-05 LATEST ▼74.4% $41.00M −$91.00M '26 Q2 26-08-05
Investor Update
Investor event
2026-10-20
Arcus Biosciences, Inc. (RCUS) October 2026 Investor Update
Scheduled
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-15
Arcus Biosciences, Inc. (RCUS) September 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-05
Arcus Biosciences, Inc. (RCUS) Q2 2026 Earnings Call Transcript
Confident tone Belzutafan durability and HIF2 mechanism thesis ARC-20 platform study and data readouts Competitive positioning after LightSpark 012 failure
Revenue
$41.00M
▼ 74.4% YoY
Diluted EPS
$-0.72
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-09
Arcus Biosciences, Inc. (RCUS) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-05
Arcus Biosciences, Inc. (RCUS) Q1 2026 Earnings Call Transcript
Confident tone Cascadifan lead program and differentiation Frontline RCC strategy and combinations PEEK-1 Phase 3 enrollment and timeline
Revenue
$17.00M
▼ 39.3% YoY
Diluted EPS
$-1.02
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-03-09
Arcus Biosciences, Inc. (RCUS) March 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q4
2026-02-25
Arcus Biosciences, Inc. (RCUS) Q4 2025 Earnings Call Transcript
Confident tone Frontline TKI-sparing strategy Casdatifan HIF2a inhibitor differentiation Peak One Phase 3 in IO-experienced RCC
Revenue
$33.00M*
▲ 26.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q2
2025-08-06
Arcus Biosciences, Inc. (RCUS) Q2 2025 Earnings Call
Revenue
$160.00M
▲ 310.3% YoY
Diluted EPS
$0.00
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-06
Arcus Biosciences, Inc. (RCUS) Q1 2025 Earnings Call Transcript
Confident tone Casdatifan (cas) program prioritization ASCO oral presentation and data flow Casdatifan combinations and earlier-line opportunity
Revenue
$28.00M
▼ 80.7% YoY
Diluted EPS
$-1.14
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-25
Arcus Biosciences, Inc. (RCUS) Q4 2024 Earnings Call
Revenue
$26.00M*
▼ 16.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-06
Arcus Biosciences, Inc. (RCUS) Q3 2024 Earnings Call Transcript
Confident tone Dom Zim Phase 3 trials (STAR-121, STAR-221, Pacific-8) ARC-20 study data updates and future readouts Domvanalimab (Fc-silent anti-TIGIT) and ARC-10 data
Revenue
$48.00M
▲ 50% YoY
Diluted EPS
$-1.00
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Arcus Biosciences, Inc. (RCUS) Q2 2024 Earnings Call
Revenue
$39.00M
▲ 34.5% YoY
Diluted EPS
$-1.02
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Arcus Biosciences, Inc. (RCUS) Q1 2024 Earnings Call Transcript
Confident tone Casdatifan (cas) in clear cell RCC vs. Novartis HIF-2 Quemliclustat (quemli) in pancreatic cancer ASCO 2024 oral presentations and upcoming catalysts
Revenue
$145.00M
▲ 480% YoY
Diluted EPS
$-0.05
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-21
Arcus Biosciences, Inc. (RCUS) Q4 2023 Earnings Call Transcript
Confident tone Casdatifan (AB521) HIF-2alpha inhibitor Anti-TIGIT (domvanalimab/zimberelimab, dom/zim) program Quemliclustat (quemli) CD73 inhibitor in pancreatic cancer
Revenue
$31.00M*
▼ 8.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Arcus Biosciences, Inc. (RCUS) Q3 2023 Earnings Call Transcript
Revenue
$32.00M
▼ 3% YoY
Diluted EPS
$-0.94
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-07
Arcus Biosciences, Inc. (RCUS) Q2 2023 Earnings Call
Revenue
$29.00M
▲ 7.4% YoY
Diluted EPS
$-1.04
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Arcus Biosciences, Inc. (RCUS) Q1 2023 Earnings Call
Revenue
$25.00M
▲ 38.9% YoY
Diluted EPS
$-1.09
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-28
Arcus Biosciences, Inc. (RCUS) Q4 2022 Earnings Call
Revenue
$34.00M*
▼ 90.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-02
Arcus Biosciences, Inc. (RCUS) Q3 2022 Earnings Call
Revenue
$33.00M
▲ 248.8% YoY
Diluted EPS
$-0.90
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-03
Arcus Biosciences, Inc. (RCUS) Q2 2022 Earnings Call
Revenue
$27.00M
▲ 185.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-09
Arcus Biosciences, Inc. (RCUS) Q1 2022 Earnings Call
Revenue
$18.00M
▲ 90.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-23
Arcus Biosciences, Inc. (RCUS) Q4 2021 Earnings Call
Revenue
$354.62M*
▲ 3637.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-18
Arcus Biosciences, Inc. (RCUS) Q3 2021 Earnings Call
Revenue
$9.46M
▼ 85.3% YoY
Diluted EPS
$-1.11
▼ 3800% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Arcus Biosciences, Inc. (RCUS) Q2 2021 Earnings Call Transcript
Revenue
$9.46M
▲ 440.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–24 of 24 earnings calls
Key facts CIK 1724521 CUSIP 03969F109 13F (30d) 6 filings 6 filers Visit website Investor relations